# Sermorelin Legal — Frequently asked questions about U.S. regulatory status

> Plain-English answers to the most common questions about sermorelin's legal status in the United States: FDA approval, the 2008 withdrawal, 503A compounding, DEA scheduling, and the WADA prohibition.

Direct answers, every one sourced. Where a question turns on jurisdictional facts, the answer names the agency and the document.

## Is sermorelin legal in the United States?

Sermorelin is a prescription-only legend drug in the United States. It is not a controlled substance under the federal Controlled Substances Act [17]. It is legal to possess by valid prescription from a licensed prescriber, and it is illegal to distribute without one. There is currently no FDA-approved finished sermorelin product on the U.S. market; dispensing in the U.S. is via 503A patient-specific compounding pharmacies or 503B outsourcing facilities, under the FDA's interim 503A bulks framework pending final Pharmacy Compounding Advisory Committee rulemaking [13][14]. Whether any specific use is lawful for any specific person in any specific jurisdiction depends on state pharmacy and medical board rules in addition to federal law — consult a licensed attorney or pharmacist in the relevant state.

## Is sermorelin FDA-approved?

Sermorelin acetate was FDA-approved twice — first in 1990 as a diagnostic provocative agent for pituitary growth hormone evaluation, and again in 1997 as a once-daily subcutaneous treatment for pediatric idiopathic growth hormone deficiency [6][13]. The sponsor voluntarily discontinued both NDAs in 2008, and FDA withdrew marketing approval administratively effective June 18, 2009 [13]. There is no FDA-approved finished sermorelin product currently on the U.S. market. In March 2013 the agency published a Federal Register notice (78 FR 14296) formally determining that the withdrawal was 'not for reasons of safety or effectiveness,' preserving the pathway for a future ANDA filing on the previously approved strengths [13].

## Why was the original sermorelin product withdrawn in 2008?

The withdrawal was a commercial sponsor decision, not a regulatory action against the product. FDA's 2013 Federal Register determination explicitly states that the discontinued strengths 'were not withdrawn from sale for reasons of safety or effectiveness' [13]. The distinction matters legally: a safety-or-effectiveness withdrawal would have foreclosed future ANDA filings on those strengths, while a non-safety commercial withdrawal preserves that pathway and informs FDA's treatment of the substance in the 503A compounding framework [13][14]. The agency's published determination is the cleanest primary source on the question.

## Is compounded sermorelin legal?

Compounded sermorelin has historically been dispensed in the United States under Section 503A of the Federal Food, Drug, and Cosmetic Act, which authorizes licensed compounding pharmacies to prepare patient-specific compounded medications pursuant to an individual prescription [14]. The FDA's interim 503A bulks list — defined in the agency's most recent guidance in 2024 — sorts nominated bulk substances into Category 1 (eligible pending final rulemaking; enforcement discretion exercised), Category 2 (significant safety concerns; not permitted), and Category 3 (insufficient information) [14]. Sermorelin has been treated as eligible for 503A compounding under this framework. The Pharmacy Compounding Advisory Committee (PCAC) is the FDA advisory body that ultimately recommends permanent status. Categorization is contingent and has shifted for several other peptides — a September 2024 FDA action removed AOD-9604, CJC-1295, ipamorelin, thymosin alpha-1, and Selank from Category 2 pending PCAC review [20]. The legal posture of compounded sermorelin specifically should be confirmed with a licensed pharmacist or attorney in the relevant state at the time of any specific use.

## Is sermorelin a controlled substance under the DEA?

No. The Drug Enforcement Administration's published schedules under 21 CFR 1308 do not enumerate sermorelin in any of Schedules I through V [17]. That distinguishes sermorelin sharply from recombinant human growth hormone (somatropin), which is subject to special restrictions under 21 USC 333(e) when distributed outside FDA-approved indications [17]. Non-scheduling does not mean unregulated — sermorelin remains a prescription-only legend drug, and prescribing and dispensing it is governed by FDA legend-drug rules, state pharmacy board regulation, and the 503A compounding framework. Non-scheduling means the substance is not subject to DEA registration, recordkeeping, or quota requirements that apply to scheduled substances.

## Is sermorelin on the WADA Prohibited List?

Yes. The World Anti-Doping Agency's 2025 Prohibited List, effective 1 January 2025, places sermorelin under Section S2.2.4 ('Growth Hormone Releasing Factors'), alongside CJC-1293, CJC-1295, and tesamorelin [15]. The prohibition applies both in- and out-of-competition for all athletes subject to the WADA Code. WADA's accompanying technical document on Growth Hormone Releasing Factors specifies the analytical framework and class definition that anti-doping laboratories apply [16]. For a WADA-code athlete, use of sermorelin constitutes an anti-doping rule violation regardless of competition timing.

## Can athletes use sermorelin under a Therapeutic Use Exemption?

There is no commonly granted Therapeutic Use Exemption pathway for sermorelin in WADA-code sports analogous to the controlled-medical-condition exemptions that exist for some other prohibited substances. The substance is classified as a Growth Hormone Releasing Factor under S2.2.4 with the prohibition applying at all times [15][16]. Any athlete with a question about a specific medical condition and a specific TUE application should consult their national anti-doping organization and a qualified sport-medicine clinician — this site does not provide medical or anti-doping compliance advice.

## Do I need a prescription for sermorelin?

Yes. Sermorelin is a prescription-only legend drug under U.S. law [17]. It cannot lawfully be dispensed without a valid prescription from a licensed prescriber. Marketing or selling sermorelin to consumers without a prescription — whether labeled as 'research only' or otherwise — does not change the underlying legend-drug status. State pharmacy boards enforce dispensing requirements alongside federal rules.

## How does sermorelin differ from recombinant human growth hormone in legal terms?

Both are prescription drugs, but the regulatory architecture is sharply different. Recombinant human growth hormone (rhGH, somatropin) has multiple currently FDA-approved finished drug products on the U.S. market and is treated as a Schedule III analog under the special provisions of 21 USC 333(e) when distributed outside FDA-approved indications — creating criminal-law exposure for off-label distribution that does not exist for sermorelin [17]. Sermorelin has no currently FDA-approved finished drug product and is dispensed through the 503A compounding channel, but it is not scheduled under the Controlled Substances Act at all [14][17]. The two substances also work differently mechanistically: sermorelin stimulates the pituitary to release endogenous GH and preserves somatostatin negative feedback; rhGH is exogenous GH that bypasses the pituitary entirely [7].

## How does sermorelin differ from tesamorelin?

Tesamorelin is currently the only FDA-approved long-acting GHRH analog, approved in 2010 for the treatment of HIV-associated lipodystrophy [18][19]. Structurally, tesamorelin is a stabilized GHRH(1-44) — the full-length native GHRH sequence — modified with a trans-3-hexenoic acid group at the N-terminus that confers resistance to DPP-IV cleavage and extends the effective half-life [18]. The pivotal trials supported once-daily 2 mg subcutaneous administration and demonstrated approximately 84 percent mean IGF-1 elevation, with reductions in visceral adipose tissue of roughly 15 percent over 26 weeks [18]. The legal difference is the active FDA approval: tesamorelin has a marketed finished drug product; sermorelin does not, and currently moves through the 503A compounding channel [13][14][19].

## What is the FDA 503A bulks list and how does it apply to sermorelin?

Section 503A of the Federal Food, Drug, and Cosmetic Act authorizes licensed pharmacies to compound patient-specific medications pursuant to an individual prescription. The FDA Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A — most recently revised in 2024 — defines the operative framework while the agency works toward final rulemaking [14]. Nominated bulk substances are sorted into Category 1 (eligible pending rulemaking; enforcement discretion), Category 2 (significant safety concerns; not permitted), or Category 3 (insufficient information) [14]. The Pharmacy Compounding Advisory Committee (PCAC) is the FDA advisory body whose recommendations inform the final categorization. Sermorelin has been treated as eligible under this framework, but eligibility is regulatorily contingent — the FDA's September 2024 action removing five other peptides from Category 2 pending PCAC review illustrates the active churn in the same regulatory zone [20].

## Is sermorelin approved in Europe?

There is no European Medicines Agency centrally authorized sermorelin product currently on the market. Sermorelin has not held an EMA authorization comparable to the original U.S. sermorelin acetate NDAs [22]. Where sermorelin is available in European jurisdictions, it follows national magistral or extemporaneous preparation rules where those rules permit, on a country-by-country basis. This site focuses on U.S. regulatory architecture and does not summarize European national-level rules in detail.

## Does this site sell sermorelin?

No. Sermorelin Legal does not sell sermorelin or any other substance. It is an independent editorial publisher that summarizes the peer-reviewed and regulatory record. It is not a pharmacy, not a clinic, not a law firm, and not affiliated with any vendor, compounder, prescriber, or manufacturer. All content is informational only.

## Is anything on this site legal advice?

No. Everything on this site is informational editorial content summarizing publicly available regulatory and scientific sources. For any question about whether a specific use of sermorelin is lawful for a specific person in a specific jurisdiction, consult a licensed attorney or pharmacist with current knowledge of the relevant federal and state rules. The regulatory framework — particularly the 503A bulks categorization and PCAC review schedule — has been actively shifting in 2024–2026, and any specific question should be checked against current sources at the time of inquiry.

---

An independent reading of the regulatory and scientific record — not legal advice, not medical guidance.